Literature DB >> 6324998

Expression of mammary tumor virus proteins in preneoplastic outgrowth lines and mammary tumors of BALB/cV mice.

B L Slagle, R E Lanford, D Medina, J S Butel.   

Abstract

A subline of BALB/c mice, designated BALB/cV, has been segregated which exhibits an intermediate mammary tumor incidence and which harbors a unique milk-transmitted virus. Six stable hyperplastic alveolar nodule outgrowth lines were established from chemical carcinogen-treated and hormonally stimulated mice. Tumor incidences exhibited by the individual preneoplastic lines ranged from 22 to 95%; no differences in tumor-producing capability were observed when lines were transplanted in virus-negative (BALB/c) or virus-positive (BALB/cV) animals. Viral antigen expression was monitored using antisera prepared against C3H mouse mammary tumor virus (MMTV) proteins. The preneoplastic lines exhibited more virus antigenpositive cells in a peroxidase-antiperoxidase immunocytochemical assay than did primary tumors which arose from the hyperplastic alveolar nodule transplants. Analysis of BALB/cV preneoplastic and tumor tissue by metabolic labeling and by protein electroblotting methodologies revealed that viral precursor and structural proteins were expressed in both types of tissue; the polypeptides were similar in molecular weight to those encoded by exogenous MMTVs. These studies demonstrate that the coding capacity of the BALB/cV isolate of MMTV is similar to that of known MMTV isolates and that each of the BALB/cV structural polypeptides shares group-specific antigenic determinants with the analogous protein encoded by MMTV from the C3H mouse. The hyperplastic outgrowth lines established in the BALB/cV subline provide an additional system for the study of mammary tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6324998

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  11 in total

1.  Association of a cellular heat shock protein with simian virus 40 large T antigen in transformed cells.

Authors:  E T Sawai; J S Butel
Journal:  J Virol       Date:  1989-09       Impact factor: 5.103

2.  Hepatitis B virus transactivator X protein is not tumorigenic in transgenic mice.

Authors:  T H Lee; M J Finegold; R F Shen; J L DeMayo; S L Woo; J S Butel
Journal:  J Virol       Date:  1990-12       Impact factor: 5.103

3.  Fluctuation of simian virus 40 (SV40) super T-antigen expression in tumors induced by SV40-transformed mouse mammary epithelial cells.

Authors:  J S Butel; C Wong; B K Evans
Journal:  J Virol       Date:  1986-11       Impact factor: 5.103

4.  Hepatitis B virus X protein interferes with cellular DNA repair.

Authors:  S A Becker; T H Lee; J S Butel; B L Slagle
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

5.  Investigations on etiology of Crohn's disease. Humoral immune response to stress (heat shock) proteins.

Authors:  D C Markesich; E T Sawai; J S Butel; D Y Graham
Journal:  Dig Dis Sci       Date:  1991-04       Impact factor: 3.199

6.  Detection and characterization of a glycoprotein encoded by the mouse mammary tumor virus long terminal repeat gene.

Authors:  C Brandt-Carlson; J S Butel
Journal:  J Virol       Date:  1991-11       Impact factor: 5.103

7.  Hepatitis B virus X protein interacts with a probable cellular DNA repair protein.

Authors:  T H Lee; S J Elledge; J S Butel
Journal:  J Virol       Date:  1995-02       Impact factor: 5.103

Review 8.  Evolution of animal models in cancer vaccine development.

Authors:  Wei-Zen Wei; Richard F Jones; Csaba Juhasz; Heather Gibson; Jesse Veenstra
Journal:  Vaccine       Date:  2015-08-01       Impact factor: 3.641

9.  Modification of simian virus 40 large tumor antigen by glycosylation.

Authors:  D L Jarvis; J S Butel
Journal:  Virology       Date:  1985-03       Impact factor: 3.616

10.  Regulation of the oncogenic phenotype by the nuclear body protein ZC3H8.

Authors:  John A Schmidt; Keith G Danielson; Emily R Duffner; Sara G Radecki; Gerard T Walker; Amber Shelton; Tianjiao Wang; Janice E Knepper
Journal:  BMC Cancer       Date:  2018-07-24       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.